

****First Published Summer 2020, now updating per order****

MasterVIEW: New vaccines forecast USA (CAT: VAMS001)

Product Name	:	MasterVIEW: New vaccines forecast USA
Description	:	Global vaccine commercial opportunity assessment, global market forecast
Contents	:	Executive presentation (> 70 slides.pdf) ¹ + 1 x MS-Excel workbook
Therapeutic Area	:	New vaccine products
Publication date	:	Summer 2020
Catalogue No	:	VAMS001

Background

The development of a truly 'new' vaccine for which no previous precedent exists, is an uncommon event within the vaccine industry. According to **VacZine Analytics**, only 7 new vaccines have been FDA licensed in the last 20 years which include, more recently, vaccines such as those for Ebola virus disease (EVD), dengue virus disease and *meningococcal* disease serogroup b. Paradoxically, this low success rate does not reflect a lack of R&D focus on new vaccines. For example, **VacZine Analytics** estimates that of nearly 1000 clinical trials initiated since 2014, approximately 40% were focused on new vaccines (oncology and non-oncology indications)².

The **SARS-CoV-2 [COVID-19]** pandemic, which emerged early in 2020, has greatly increased emphasis on new vaccine development. The pandemic has affirmed the high importance of prophylactic vaccination as a tool to mitigate the alarming health and economic impacts brought by new infectious diseases. Ground-breaking mRNA-based technologies such as **mRNA-1273 (Moderna TX)** and **BNT162b1 (Pfizer/BioNTech)** hold promise and have entered pivotal, Phase III studies (Summer 2020). The predicted timelines from project initiation to expected FDA approval of COVID-19 vaccines are both unprecedented and controversial causing much debate among industry analysts. If new COVID-19 vaccines show any efficacy signal in late-stage clinical trials, especially those based on mRNA technologies, **VacZine Analytics** predicts a huge 'shake-up' in vaccine new product development over the coming years. To fully take advantage of this coming era, the selection and prioritization of new pathogen/disease opportunities will be more critical than ever as competitors race to achieve dominance and protect their existing product franchises based on 'older' more traditional vaccine technologies.

VacZine Analytics, MasterVIEW is a brand new product line for 2020 which aims to address a growing need for a detailed comparative landscape view or commercial attractiveness audit of multiple new vaccine product opportunities for strategic planning, M&A and/or formulation of R&D strategy. **MasterVIEW** draws upon more than **65 global new vaccine product opportunities** by pathogen/disease/sub-segment already analysed in the VacZine Analytics' **MarketVIEW** range.

MasterVIEW is an essential part of any organisations' new vaccine product planning initiative [see inside].

¹ This slide number is for the Section 1,2 and 3 of the analysis

² VacZine Analytics: Strategic Pipeline Review (VAMV084)

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to new vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference and FDA meeting proceedings etc. Previously published research by **VacZine Analytics** in the fields of all other new vaccines from our comprehensive [MarketVIEW](#) range have been utilized in this analysis.

PRODUCT CONTENTS:

Published Summer 2020 (CAT No: VAMS001)

***This product is a [summary presentation \(.pdf\)](#), [1 x MS-Excel workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)³

Contents

Author's notes

Executive summary and key findings (~8 slides)

[SECTION 1] Background and classification of 67 global new vaccines (~21 slides)

[SECTION 2] 52 new USA vaccines: research and development (~12 slides)

[SECTION 3] 52 new USA vaccines: analysis and forecasts to 2035 (~26 slides)

*****OPTIONAL*****

[SECTION 4] 52 new vaccines: individual USA disease and forecast profiles to 2035 (~100 slides)

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >200 slides fully referenced/sourced⁴. Available in .pdf form

Contents – 1 x MS Excel-based workbook (detailing all major outputs to .pdf)

Worksheets = ~15 interconnected

³ Full contents i.e. title per slide is proprietary and only visible on license purchase

⁴ If all Sections (1-4) are taken

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$contact us**/ GBP **£contact us**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

On-line prices Summer include discounts and are converted from list price in US dollars (subject to currency fluctuations)

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.




VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – proprietary



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It cannot be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and "the spiral logo" are UK Registered Trademarks, 2009

